Stock Track | DexCom Soars 5.64% Intraday on Analyst Upgrades and AI Product Expansion

Stock Track

Feb 13

DexCom Inc. (DXCM) experienced a significant price surge intraday, with shares soaring 5.64% during Friday's trading session. The medical device company's stock moved sharply higher as market sentiment turned positive.

The upward movement appears to be driven by a combination of positive analyst actions and strategic product developments. Multiple financial institutions issued favorable research notes on DexCom, including Mizuho raising its price target to $90 from $78 and Barclays increasing its target to $72 from $71. Other firms including Morgan Stanley, Bernstein, and BTIG maintained their positive ratings on the stock.

Additionally, DexCom announced the expansion of AI-enabled features for its Stelo over-the-counter glucose biosensor, adding expanded Smart Food Logging and a broad nutrition database. This strategic move deepens the company's push into consumer-focused digital health and comes after the company reported better-than-expected Q4 2025 results, with sales reaching US$1.26 billion for the quarter.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1115203199"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1115203199\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1115203199?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-13 22:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1115203199","market":"nz","top_or_hot":-1,"title":"Stock Track | DexCom Soars 5.64% Intraday on Analyst Upgrades and AI Product Expansion","media":"Stock Track","content":"<p>DexCom Inc. (DXCM) experienced a significant price surge intraday, with shares soaring 5.64% during Friday's trading session. The medical device company's stock moved sharply higher as market sentiment turned positive.</p><p>The upward movement appears to be driven by a combination of positive analyst actions and strategic product developments. Multiple financial institutions issued favorable research notes on DexCom, including Mizuho raising its price target to $90 from $78 and Barclays increasing its target to $72 from $71. Other firms including Morgan Stanley, Bernstein, and BTIG maintained their positive ratings on the stock.</p><p>Additionally, DexCom announced the expansion of AI-enabled features for its Stelo over-the-counter glucose biosensor, adding expanded Smart Food Logging and a broad nutrition database. This strategic move deepens the company's push into consumer-focused digital health and comes after the company reported better-than-expected Q4 2025 results, with sales reaching US$1.26 billion for the quarter.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | DexCom Soars 5.64% Intraday on Analyst Upgrades and AI Product Expansion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | DexCom Soars 5.64% Intraday on Analyst Upgrades and AI Product Expansion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-13 22:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>DexCom Inc. (DXCM) experienced a significant price surge intraday, with shares soaring 5.64% during Friday's trading session. The medical device company's stock moved sharply higher as market sentiment turned positive.</p><p>The upward movement appears to be driven by a combination of positive analyst actions and strategic product developments. Multiple financial institutions issued favorable research notes on DexCom, including Mizuho raising its price target to $90 from $78 and Barclays increasing its target to $72 from $71. Other firms including Morgan Stanley, Bernstein, and BTIG maintained their positive ratings on the stock.</p><p>Additionally, DexCom announced the expansion of AI-enabled features for its Stelo over-the-counter glucose biosensor, adding expanded Smart Food Logging and a broad nutrition database. This strategic move deepens the company's push into consumer-focused digital health and comes after the company reported better-than-expected Q4 2025 results, with sales reaching US$1.26 billion for the quarter.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DXCM","symbol_name":"德康医疗","start_time":0,"source_url":"","article_id":"1115203199","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1115203199","pubTimestamp":1770993748,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"DexCom Inc. (DXCM) experienced a significant price surge intraday, with shares soaring 5.64% during Friday's trading session. The medical device company's stock moved sharply higher as market...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DXCM":"德康医疗"},"translate_title":"个股追踪|DexCom盘中大涨5.64%因分析师升级和AI产品扩张","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DXCM":1},"content_text":"DexCom Inc. (DXCM) experienced a significant price surge intraday, with shares soaring 5.64% during Friday's trading session. The medical device company's stock moved sharply higher as market sentiment turned positive.The upward movement appears to be driven by a combination of positive analyst actions and strategic product developments. Multiple financial institutions issued favorable research notes on DexCom, including Mizuho raising its price target to $90 from $78 and Barclays increasing its target to $72 from $71. Other firms including Morgan Stanley, Bernstein, and BTIG maintained their positive ratings on the stock.Additionally, DexCom announced the expansion of AI-enabled features for its Stelo over-the-counter glucose biosensor, adding expanded Smart Food Logging and a broad nutrition database. This strategic move deepens the company's push into consumer-focused digital health and comes after the company reported better-than-expected Q4 2025 results, with sales reaching US$1.26 billion for the quarter.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}